Transcutaneous Carbon Dioxide Therapy Significantly Accelerates Diabetic Foot Ulcer Healing: A Multicentre Randomised Controlled Trial
<b>Background/Objectives:</b> Diabetic foot ulcers (DFUs) represent common and severe complications of diabetes mellitus (DM). The aim of our parallel-group, open-label, superiority, multicentre randomised controlled trial (RCT) was to evaluate the effectiveness of transcutaneous gaseous carbon dioxide therapy (hereinafter CO<sub>2</sub> therapy) in ulcer healing in patients with non-healing DFUs. <b>Methods:</b> A total of 115 participants (89 males and 26 females, aged 65.7 ± 10.9 years) with a non-healing DFU were randomised to the intervention (76 participants) and control (39 participants) group. Participants in the intervention group received standard of care, combined with CO<sub>2</sub> therapies administered every weekday for four consecutive weeks. Participants in the control group received only standard of care. <b>Results:</b> After 4 weeks, 49 (64.5%) ulcers in the intervention group healed, compared with three (7.7%) in the control group (primary outcome). The percentage ulcer area reduction from baseline (secondary outcome) was significantly larger (<i>p</i> ≤ 0.001) in patients from the intervention group, with the median value 100% (18.4-100%), compared to the patients from the control group, with the median value 40% (-300-100%). Patients receiving CO<sub>2</sub> therapy had 35.4-fold higher odds of ulcer healing versus controls (OR 35.4, 95% CI 6.68-187.53; <i>p</i> < 0.001), and in multivariate logistic regression, CO<sub>2</sub> therapy remained independently associated with healing, while larger baseline ulcer area was associated with lower odds of healing (OR 0.654, 95% CI 0.438-0.977; <i>p</i> = 0.038). No adverse effects were reported. <b>Conclusions:</b> CO<sub>2</sub> therapy significantly contributes to ulcer healing in patients with non-healing DFUs, with no observable adverse effects, demonstrating significant potential as an effective and safe complementary treatment of DFUs in conjunction with standard of care.
Authors
- Anica Badanjak
- Igor Frangež (ORCID: https://orcid.org/0000-0001-9963-8810)
- Skender Veliu
- Tamara Poljičanin
- Marco Meloni (ORCID: https://orcid.org/0000-0002-3180-009X)
- Tomislav Bulum (ORCID: https://orcid.org/0000-0003-4808-2968)
- Helena Ban Frangež
- Željko Metelko
- Julija Križaj
- Nikolaos Papanas
- Miloš Potkonjak
Institutions
- University of Rome Tor Vergata (IT)
- Democritus University of Thrace (GR)
- University of Ljubljana (SI)
- University of Zagreb (HR)
- Ljubljana University Medical Centre (SI)
- Perutnina Ptuj (Slovenia) (SI)
- Klinička bolnica Merkur (HR)
- Policlinico Tor Vergata (IT)
- Croatian Personal Data Protection Agency (HR)
- School of Business and Management Novo Mesto (SI)
- Polyclinic General Hospital (GR)
Publication Details
- Journal
- Biomedicines
- Published
- 2026-02-13
- DOI
- https://doi.org/10.3390/biomedicines14020422
- Primary Topic
- Diabetic Foot Ulcer Assessment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00